Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Increasing diagnosis and treatment rates, and substantial unmet need combine to make HCV a high-growth opportunity over the next several years. Coverage of the two major brands of pegylated interferon-alfas (peg-IFN), Roche’s Pegasys (peginterferon-alfa-2a) and Merck’s PegIntron (peginterferon-alfa-2b), varies greatly between the private and Medicare channels. Three Rivers Pharmaceuticals’ Infergen (Interferon alfacon-1), a more recent market entrant with less favorable dosing, trails the peg-IFNs in coverage and tiering.

Because there is essentially only one choice for HCV drug treatment—combination therapy of IFN and ribavirin (Roche’s Copegus, Merck’s Rebetol, generics)—and there are limited options for treatment of non-responders, emerging agents that can offer improved efficacy will have a substantial market opportunity. Furthermore, the high current and historical failure rates for IFN/ribavirin combination therapy mean there is a large population of HCV patients awaiting new options that will likely take the first new therapy that is available and reimbursed. Vertex and Merck are racing to bring telaprevir and boceprevir, respectively, to market to try and capture this large population of HCV non-responders.

Using tiering and restrictions data from Fingertip Formulary, as well as insight from 51 pharmacy directors, this report determines the key trends in reimbursement of HCV treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.

Related Reports

Formulary Advantages in Type 2 Diabetes:Rebates and discounts dictate the formulary position of branded therapies among some U.S. health plans.

According to the Centers for Disease Control and Prevention (CDC), an estimated 25.8 million people in the United States have diabetes. Diabetes is the leading cause of kidney failure, nontraumatic lo...

View Details

Formulary Advantages in Atrial Fibrillation: How Will MCO Size Affect the Design of Factor Xa Formularies?

In the coming years, atrial fibrillation (AF) patients will increasingly have more choice for anticoagulation therapy. Although Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and emerging facto...

View Details

Formulary Advantages in Asthma and COPD Therapies: Formulary Advantages in Asthma and COPD Therapies - Abstract

The market for asthma and chronic obstructive pulmonary disease (COPD) has grown notably in recent years because of increasing prevalence and diagnosis rates for both conditions as well as the greater...

View Details

Formulary Advantages in Psychiatric Drugs: Medicare plans readily employ cost-sharing measures and formulary restrictions to direct early use of generics and preferred brands for psychiatry.

According to the National Institute of Mental Health, each year tens of millions of Americans are affected by mental illness. Although significant strides have been made toward understanding the patho...

View Details